Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs …

Global tuberculosis incidence has declined marginally over the past decade, and
tuberculosis remains out of control in several parts of the world including Africa and Asia …

Background The bedaquiline–pretomanid–linezolid regimen has been reported to have
90% efficacy against highly drug-resistant tuberculosis, but the incidence of adverse events …

Background Patients with highly drug-resistant forms of tuberculosis have limited treatment
options and historically have had poor outcomes. Methods In an open-label, single-group …

Background Treatment of multidrug-resistant tuberculosis requires long-term therapy with a
combination of multiple second-line drugs. These drugs are associated with numerous …

A clear understanding of the genetic basis of antibiotic resistance in Mycobacterium
tuberculosis is required to accelerate the development of rapid drug susceptibility testing …

Large studies on bedaquiline used to treat multidrug-resistant (MDR-) and extensively drug-
resistant tuberculosis (XDR-TB) are lacking. This study aimed to evaluate the safety and …

Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain
low globally. Availability of newer drugs has given scope to develop regimens that can be …

Background Addition of bedaquiline to treatment for multidrug-resistant tuberculosis was
associated with an increased risk of death in a phase 2b clinical trial, resulting in caution …

The emergence of antimicrobial resistance against Mycobacterium tuberculosis, the leading
cause of mortality due to a single microbial pathogen worldwide, represents a growing threat …